EMA Releases New Summary of Biosimilar Regulatory Procedures

Posted 11 April 2012 By Alexander Gaffney

The European Medicines Agency (EMA) released a new regulatory procedure document on biosimilar medicines which it hopes will consolidate a number of regulatory and procedural questions already existing in a number of locations.

The document "complements existing guidance documents on innovative products and should be read in conjunction with the Agency's scientific guidelines on biosimilars," EMA said in a press release.

The document lists 43 questions and answers related to the development and regulatory submission of biosimilar products.


Read more:

EMA - European Medicines Agency publishes new document on regulatory procedural advice on similar biological medicines

EMA - EMA Procedural advice for users of the centralised procedure for similar biological medicinal products applications 

Share this article:

Categories: EMA

Tags: Procedural Document, Biogeneric, Latest News, biosimilar, Biosimilars, Follow-on Biologics, regulatory

Regulatory Exchange: Latest Updates From the Community